Acadia Pharmaceuticals Inc’s drug for psychosis linked to Parkinson’s disease was approved in the United States on Friday, becoming the first treatment for the condition to get a nod in the country. The U.S. Food and Drug Administration, however, asked Acadia to include a black-box warning, its strictest warning, on the drug’s label for an increased risk of death associated with its use in older people. The drug, Nuplazid, is expected to be priced at $13,500 per patient for a year and reach more that $1 billion in sales in 2021, according to Leerink analyst Paul Matteis.
Go here to read the rest:
U.S. approves first drug for psychosis linked to Parkinson’s
